Becker Hewes

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef et al. · Journal of Clinical Oncology · 2009 · 640 citations

Pharmacy, Oncology, Pharmacotherapy +11

Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice

Liguo Niu, Simona Strahotin, Becker Hewes et al. · The Journal of Immunology · 2007 · 171 citations · Full text

Life Sciences, Hematology, Immunology +17

A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.

Jörge E. Cortes, Hagop M. Kantarjian, Michele Baccarani et al. · Blood · 2006 · 53 citations

Medicine, Oncology, Pharmacotherapy +16

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Leslie A. Andritsos, John C. Byrd, Jeffrey A. Jones et al. · Blood · 2010 · 47 citations

Pharmacy, Oncology, Pharmacotherapy +14

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

Toshihiko Doi, Becker Hewes, Tomoyuki Kakizume et al. · Cancer Science · 2017 · 40 citations · Full text

Medicine, Oncology, Pharmacology +15